Novel pro-inflammatory interleukins: potential therapeutic targets in rheumatoid arthritis - 01/01/01
Natacha Bessis * , Marie-Christophe Boissier*Correspondence and reprints: UPRES EA-2361, UFR Léonard de Vinci, 74 rue Marcel Cachin, 93017 Bobigny cedex, France
Voir les affiliationspages | 5 |
Iconographies | 0 |
Vidéos | 0 |
Autres | 0 |
Résumé |
Among potential targets for nonspecific anti-inflammatory immunointervention, three proinflammatory interleukins (ILs) have recently been found to play a pivotal role in rheumatoid arthritis (RA). IL-15 has both chemoattractant and proinflammatory properties and may promote bone destruction. IL-17, a product of T lymphocytes, has proinflammatory effects and induces production of metalloproteinases such as MMP-1. IL-18 not only has proinflammatory, angiogenic, and chemoattractant effects but also promotes cartilage destruction. These cytokines are potential targets for specific or nonspecific anti-inflammatory therapy. Thus, blocking IL-15 by its receptor reduces the severity of experimental collagen-induced arthritis (CIA). In this model, IL-17 levels fall after administration of anti-inflammatory cytokines such as IL-4 or IL-13. Finally, monoclonal anti-IL-18 antibodies prevent streptococcal cell wall arthritis, and IL-18 binding protein, which is a naturally occurring IL-18 inhibitor, prevents CIA.
Mots clés : inflammation ; interleukin-15 ; interleukin-16 ; interleukin-17 ; interleukin-18 ; rheumatoid arthritis.
Plan
Vol 68 - N° 6
P. 477-481 - décembre 2001 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?